This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.
Get full access to this article
View all access options for this article.
References
1.
GillisJC, BrogdenRN.Ketorolac – A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs. 1997;53:139–188.
StromBL, BerlinJA, KinmanJL, Parenteral ketorolac and risk of gastrointestinal and operative site bleeding: A postmarketing surveillance study. JAMA. 1996;275:376–382.
4.
Ketorolac tromethamine injection, solution [product information]. Lake Forest, IL: Hospira, Inc; June 2011.
5.
ParsonsHA, ShukkoorA, QuanH, Intermittent subcutaneous opioids for the management of cancer pain. J Palliat Med. 2008;11:1319–1324.
6.
BlackwellN, BangmanL, HughesM, MelzackD, TrotmanI.Subcutaneous ketorolac – a new development in pain control. Palliat Med. 1993;7:63–65.
BlackwellN, BanghamL, HughesM, MelzackD, TrotmanI.Treatment of resistant pain in hypertrophic pulmonary arthropathy with ketorolac. Thorax. 1993;48:401.
9.
RipamontiC, ChiaraT, ZeccaE, RodriguezCH, De ConnoF.Continuous subcutaneous infusion of ketorolac in neuropathic pain unresponsive to opioid and adjuvant drugs: A case report. Tumori. 1996;82:413–415.
10.
HughesA, WilcockA, CorcoranR.Ketorolac: subcutaneous infusion for cancer pain. J Pain Symptom Manage. 1997;13:315–316.
11.
De ConnoF, ZeccaE, MartiniC, RipamontiC, CaraceniA, SaitaL.Tolerability of ketorolac administed via continuous subcutaneous infusion in cancer pain: A preliminary report. J Pain Symptom Manage. 1994;9:119–121.
12.
MyersKG, TrotmanIF.Use of ketorolac by continuous subcutaneous infusion for the control of cancer-related pain. Postgrad Med J. 1994;70:359–362.
13.
CampbellL, PlummerJ, OwnH, CzuchwickiA, IlsleyA.Effect of short-term ketorolac infusion of recovery following laparoscopic day surgery. Anaesth Intens Care. 2000;28:654–659.
14.
CarvalhoB, LemmensHJ, TingV, AngstMS.Postoperative subcutaneous instillation of low-dose ketorolac but not hydromorphine reduces wound exudates concentrations of interleukin-6 and interleukin-10 and improves analgesia following cesarean delivery. J Pain. 2013;14:48–56.
